{"filing":{"accession_number":"0001104659-26-082906","cik":"0001640266","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"tm2620191d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/tm2620191d1_8k.htm"},"events":[{"id":17519,"run_id":15693,"accession_number":"0001104659-26-082906","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Voyager disclosed positive preclinical GLP toxicology and efficacy data for VY1706 presented at the Alzheimer's Association International Conference, demonstrating favorable tolerability in non-human primates with up to 75% tau protein lowering and broad CNS delivery. This represents a material operational/clinical milestone for a gene therapy program advancing toward human trials (IND clearance received June 2026, dosing planned for H2 2026), affecting investor assessment of the company's pipeline progress and therapeutic potential.","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16023,"accession_number":"0001104659-26-082906","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Voyager disclosed positive preclinical GLP toxicology and efficacy data for VY1706 presented at the Alzheimer's Association International Conference, demonstrating favorable tolerability in non-human primates with up to 75% tau protein lowering and broad CNS delivery. This represents a material operational/clinical milestone for a gene therapy program advancing toward human trials (IND clearance received June 2026, dosing planned for H2 2026), affecting investor assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:45:36.938500+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16023,"accession_number":"0001104659-26-082906","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Voyager disclosed positive preclinical GLP toxicology and efficacy data for VY1706 presented at the Alzheimer's Association International Conference, demonstrating favorable tolerability in non-human primates with up to 75% tau protein lowering and broad CNS delivery. This represents a material operational/clinical milestone for a gene therapy program advancing toward human trials (IND clearance received June 2026, dosing planned for H2 2026), affecting investor assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:45:36.938500+00:00","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-07-13"}]}